Clinical Analysis of PD-1 Inhibitor Combined with Lenalidomide in Treatment of Relapsed CD5+Diffuse Large B-Cell Lymphoma

VernacularTitle:PD-1抑制剂联合来那度胺治疗复发CD5+弥漫大B细胞淋巴瘤临床分析
Author: Ya-Ping WANG ¹ ; Xue-Ya ZHANG
Author Information

1. 福建医科大学附属第二医院血液科,福建泉州 362000
Keywords: PD-1 inhibitor; lenalidomide; CD5+diffuse large B-cell lymphoma; interleukin-10
From: Journal of Experimental Hematology 2024;32(4):1112-1116
CountryChina
Language:Chinese
Abstract: Objective:To investigate the clinical characteristics and treatment of relapsed CD5+diffuse large B-cell lymphoma(DLBCL).Methods:The data of a patient with CD5+DLBCL was collected,and its clinical characteristics and treatment outcome were analyzed.Results:The patient developed hemophagocytic syndrome and achieved complete remission(CR)after 6 cycles of R-ECHOP chemotherapy,then relapsed.After 2 cycles of PD-1 inhibitor combined with lenalidomide treatment,the patient achieved CR again accompanied by a decrease of interleukin(IL)-10 expression level.After a total of 15 cycles of chemotherapy,the patient remained in CR for 24 months,and the level of IL-10 remained in the normal range.Conclusion:PD-1 inhibitor combined with lenalidomide regimen may be a new treatment for relapsed CD5+DLBCL.